Among responding patients in the T-VEC arm, median time to response was 4.1 months, and more than half experienced ≥ 25% increase in the size of lesions or appearance of new lesions before achieving a response. This pattern of pseudoprogression is consistent with that seen with other immunotherapies19–23The full quote is above.
It reads as half the responders are having psuedoprogression is how I see that.
And then haven’t looked at your other article of 15%, but sounds like much higher than other immunotherapies.
And this is what CF33 is meant to outperform, and they’ve compared to preclinically, so don’t think it would be a stretch for CF33 rates to be higher still.
Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting, page-247
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.8¢ |
Change
-0.013(3.91%) |
Mkt cap ! $67.56M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 31.5¢ | 30.5¢ | $516.8K | 1.663M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 413713 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 168703 | 7 |
View Market Depth
| Last trade - 15.06pm 23/07/2025 (20 minute delay) ? |
| IMU (ASX) Chart |